StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.2
  1. Startseite
  2. /Verbindung

Butaperazin

Butaperazine

HCID 12598
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
653-03-2
Standard-SMILES
CCCC(=O)c1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2
InChIKey
DVLBYTMYSMAKHP-UHFFFAOYSA-N
Summenformel
C24H31N3OS
Durchschnittliche Molmasse
409,6 g/mol
Monoisotopische Masse
409,21878379

Überblick

Butaperazine is a member of phenothiazines.

Namen und Bezeichner

Bevorzugter Name
Butaperazine
IUPAC
1-[10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazin-2-yl]butan-1-one
Lokaler Name
Butaperazin
Englischer Name
butaperazine
Summenformel
C24H31N3OS
Molmasse
409.59

Namen und Synonyme

BUTAPERAZINEButyrylperazine653-03-2MegalectilRandolectilEmerexRepoiseRiker 595Bayer 1362ButyrylyperazinePerazine, butyryl-Perazine, (1-oxobutyl)-
Weitere Namen anzeigen
Butaperazina1-[10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazin-2-yl]butan-1-one1-[10-[3-(4-Methyl-1-piperazinyl)propyl]-10H-phenothiazin-2-yl]-1-butanone1-Butanone, 1-[10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazin-2-yl]-
AHR-712AHR 712AHR-3000RIKER-595BAYER-13621-Butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazin-2-yl)-TXP4T9106S1-(10-(3-(4-Methyl-1-piperazinyl)propyl)phenothiazin-2-yl)-1-butanone

Datenbank-Bezeichner

CAS
653-03-2
PubChem CID
12598
DTXSID
DTXSID1022712

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
5
Polarare Oberfläche (TPSA)
52,1 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
7
Schwere Atome
29
Formalladung
0
Komplexität
536

Experimentelle und physikochemische Eigenschaften

LogP4.83
Solubility · 2 Einträge

1 G IN 400 ML WATER; SOL IN DIMETHYLFORMAMIDE; SPARINGLY SOL IN ALCOHOL & METHANOL; INSOL IN ACETONE, CHLOROFORM, & ETHER /MALEATE/

SOL OF THE FREE BASE IN ARTIFICIAL INTESTINAL JUICE WAS 283 MG/100 ML AT PH 6, DECR TO 4.9 MG/100 ML AT PH 8

Human DrugsPharmaceuticals
Boiling Point270-280 °C @ 0.05 mm Hg
Melting PointMP: 180-182 °C /Maleate/
Stability/Shelf LifeUNSTABLE IN LIGHT (SUBJECT TO OXIDATIVE DEGRADATION) & EXCESSIVE HEAT /MALEATE/
Other Experimental Properties · 3 Einträge

PRACTICALLY ODORLESS & HAS MODERATELY BITTER TASTE, NOT APPRECIABLY HYGROSCOPIC /MALEATE/

BRIGHT-YELLOW POWDER /MALEATE/

Crystals from carbon tetrachloride /Maleate/

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Gefahrenhinweise

FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Sicherheit und Schutzausrüstung

Disposal Methods · 1 Eintrag

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxikologische Informationen

Interactions · 5 Einträge

THE PHENOTHIAZINES WITH LOW POTENCY...MARKEDLY AFFECT THE ACTIONS OF A NUMBER OF OTHER DRUGS, & COGNIZANCE MUST BE TAKEN OF THIS FACT. ... PATIENTS SHOULD ALSO BE WARNED TO EXPECT ENHANCEMENT OF THE EFFECTS OF ALCOHOL. ...THE PHENOTHIAZINES CAN PROMOTE HYPOTENSION, POSSIBLY DUE TO THEIR ALPHA-ADRENERGIC BLOCKING PROPERTIES. THUS, THE INTERACTION BETWEEN PHENOTHIAZINE AND ANTIHYPERTENSIVES CAN BE QUITE UNPREDICTABLE.

...CONTRAINDICATED IN COMATOSE PT WHO HAVE RECEIVED LARGE AMT OF CENTRAL NERVOUS SYSTEM DEPRESSANT DRUGS (...BARBITURATES, NARCOTICS, ETC)... /PHENOTHIAZINES/

ROUTINE ADMIN OF ANTIPARKINSONISM AGENTS SHOULD BE AVOIDED WITH MOST ANTIPSYCHOTIC DRUG REGIMENS. /PHENOTHIAZINES/

...PHENOTHIAZINES...MAY PRODUCE ADDITIVE HYPOTENSIVE EFFECTS WITH PROPRANOLOL. /PHENOTHIAZINES/

For more Interactions (Complete) data for BUTAPERAZINE (37 total), please visit the HSDB record page.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

Mechanism of Action · 2 Einträge

THERE IS AN ADENYLATE CYCLASE IN LIMBIC SYSTEM, AS WELL AS IN CAUDATE NUCLEUS, THAT IS SPECIFICALLY ACTIVATED BY DOPAMINE. ...ACTIVATION OF...ENZYME IS... BLOCKED BY...PHENOTHIAZINES. ...THERAPEUTIC EFFICACY & SIDE EFFECTS MAY RELATE TO INHIBITION OF DOPAMINE ACTIVATION OF ADENYLATE CYCLASE. /PHENOTHIAZINES/

...PHENOTHIAZINES, BLOCK DOPAMINE RECEPTORS & INCR TURNOVER RATE OF DOPAMINE IN CORPUS STRIATUM. INCR TURNOVER RATE IS BELIEVED TO BE RESULT OF NEURONAL FEEDBACK MECHANISM. ...FIRING OF.../IDENTIFIED DOPAMINERGIC NEURONS IN SUBSTANTIA NIGRA & VENTRAL TEGMENTAL AREAS/ IS INCR BY ANTIPSYCHOTIC PHENOTHIAZINES. /PHENOTHIAZINES/

Biological Half-LifeBUTAPERAZINE (10-60 MG ORALLY) HAD AVG PEAK SERUM LEVELS OF 215 NG/ML IN HUMANS AND AN INITIAL RAPID PHASE HALF-LIFE OF 4 HR AND A SLOWER PHASE HALF-LIFE OF 12 HR. SERUM BUTAPERAZINE LEVELS WERE PROPORTIONAL TO THE DOSE ADMINISTERED.
Metabolism/Metabolites · 2 Einträge

AFTER CHRONIC ADMIN OF PIPERAZINE-SUBSTITUTED PHENOTHIAZINE DRUGS...TO RATS, TISSUES CONTAINED DRUG METABOLITES, IN WHICH PIPERAZINE RING FISSION BY MULTIPLE OXIDATIVE N-DEALKYLATION HAD OCCURRED TO GIVE SUBSTITUTED ETHYLENEDIAMINE. /PIPERAZINE PHENOTHIAZINES/

IN RATS & DOGS, PRINCIPAL FECAL METABOLITES OF BUTAPERAZINE DIMALEATE RESULT FROM HYDROXYLATION OF PHENOTHIAZINE RING-SYSTEM & OXIDATIVE N-DEMETHYLATION. BUTAPERAZINE SULFOXIDE, BUTAPERAZINE SULFONE, & REDN PRODUCT OF BUTYRYL SIDE-CHAIN CARBONYL GROUP MAKE UP MINOR METABOLITES. /DIMALEATE/

Absorption, Distribution and Excretion · 3 Einträge

NEUROLEPTIC CONCN-THERAPEUTIC RESPONSE CURVES EXAMINED FOR BUTAPERAZINE IN 10 SCHIZOPHRENIC PT DURING FIRST 12 DAYS OF TREATMENT. RESULTS SHOWED BUTAPERAZINE BOUND TO RED BLOOD CELLS WAS MORE STRONGLY CORRELATED WITH THERAPEUTIC RESPONSE THAN WAS PLASMA CONCN.

IN A STUDY ON 2 GROUPS OF NONRESPONDING SCHIZOPHRENICS AND ONE GROUP OF CLINICALLY RESPONDING PT WITH AFFECTIVE DISORDERS, THE NONRESPONDERS HAD 2 TO 7 TIMES LOWER LEVELS OF BUTAPERAZINE, 40 MG TWICE DAILY, IN PLASMA AND RED BLOOD CELLS AFTER A SINGLE DOSE OR CHRONIC DOSING.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEMBL
CHEMBL1697826
ChEBI
CHEBI:135663
UNII
TXP4T9106S
EC Number
211-493-9
Nikkaji
J7.078E

Physikochemische Eigenschaften

Siedepunkt
0.05 · bp0.05 270-280°
Dichte
1.138 · 1.138±0.06 g/cm3(Predicted)
pka
7.66 · 7.66±0.10(Predicted)
Milk Concentrations
PHENOTHIAZINES ... MAY APPEAR IN MILK OF NURSING MOTHERS... /PHENOTHIAZINES, HUMAN, ORAL, IM/
Non-Human Toxicity ExcerptsBUTAPERAZINE (1 MG/KG SC) DIMINISHED EXPLORATORY BEHAVIOR IN MICE.
Antidote and Emergency Treatment · 1 Eintrag

EXTRAPYRAMIDAL SYMPTOMS...RELIEVED WITH BARBITURATES, METHYLPHENIDATE HYDROCHLORIDE...ANTI-PARKINSON DRUGS...BENZTROPINE MESYLATE...TRIHEXYPHENIDYL HYDROCHLORIDE...DIPHENHYDRAMINE HYDROCHLORIDE...IN SEVERE CASES, SUPPORTIVE THERAPY...MAINTAINING CLEAR AIRWAY & ADEQUATE HYDRATION. /HYDROCHLORIDE/

Regulatorische Informationen

FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Sicherheitsdaten

Giftige Stoffe Daten
653-03-2(Hazardous Substances Data)

EIGHT OF 10 CHRONIC SCHIZOPHRENIC PT RECEIVED A 40 MG LOADING DOSE OF BUTAPERAZINE AND THEN WERE TITRATED UNTIL A THERAPEUTIC RESPONSE WAS OBTAINED. THRICE DAILY USE OF THE DRUG SHOWED A HIGHER WHOLE BLOOD STEADY STATE DRUG PLASMA LEVEL THAN THE ONCE A DAY USE OF THE SAME TOTAL DAILY DOSE.

Verwendung und Herstellung

UsesAntipsychotic
Methods of Manufacturing · 2 Einträge

Hoerlein et al, German patent 1,120,451 (1961 to Bayer), CA 57, 4677c (1962).

1-METHYLPIPERAZINE IS CONDENSED WITH 10-(3-CHLOROPROPYL)PHENOTHIAZIN-2-YL PROPYL KETONE BY REFLUXING MIXT IN INERT SOLVENT IN PRESENCE OF DEHYDROCHLORINATING AGENT SUCH AS SODAMIDE. RESULTING BUTAPERAZINE IS THEN REACTED WITH DOUBLE EQUIMOLAR PORTION OF MALEIC ACID. ... US PATENT 2,985,654. /MALEATE/

Formulations/PreparationsTABLETS: 5, 10, & 25 MG (OF BASE AS MALEATE). /MALEATE/
Use ClassificationPharmaceuticals
General Manufacturing InformationA FEW AVAIL AGENTS...ARE NOW KNOWN TO HAVE INFERIOR ANTIPSYCHOTIC EFFECTS OR...ARE NO LONGER COMMONLY USED IN PSYCHIATRIC PT. THESE INCL BUTAPERAZINE...

Anwendungen

VerwendenAntipsychotic.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

NatriumamidNatriumhydroxid

Nachgelagerte Produkte

1-(10-(3-(4-Methyl-1-piperazinyl)-propyl)-10H-phenothiazin-2-yl)-1-butanon, (Z)-2-butendioat (1:2)